ABOUT THIS CONFERENCE
The expanse of epigenetic modulators poised as promising therapeutic targets has never been more robust. Yet, until recently, enzymatic modulators of writer and eraser classes have been the main focus of therapeutic development. Over the past few years, a relatively underexplored group of proteins have emerged as promising targets. Operating at the interface of translating histone marks, proteins such as the BET family bromodomain readers have demonstrated favorable activity when inhibited in human cancers. Therapeutic potential is evident, but with little potent and selective chemical matter available for inhibition, the biological consequence associated with disrupting epigenetic reading is largely undefined. Cambridge Healthtech Institute is proud to announce the Inaugural Targeting Epigenetic Readers conference, designed to unite academic and industry researchers for the development of chemical probes to further our understanding of the therapeutic opportunities associated with targeting reader domains.
SUGGESTED EVENT PACKAGE
September 23: Biochemical and Structure-Based Approaches to Epigenetic Drug Discovery Short Course
September 23: Characterization and Quantification of Histone Modifications Short Course
September 24 - 25: Targeting Epigenetic Readers Conference
September 25 - 26: Next-Generation Histone Deacetylase Inhibitors Conference
Featured Presentation
Peter J. Tummino, Ph.D., Head, Biology, Cancer Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline Pharmaceuticals
Featured Presentation
Cheryl H. Arrowsmith, Ph.D., Chief Scientist, Structural Genomics Consortium; Professor, Medical Biophysics; Canada Research Chair, Structural Proteomics, University of Toronto
Targeting MYCN with BET Bromodomain Inhibitors in Neuroblastoma
Kimberly Stegmaier, M.D., Associate Professor, Department of Pediatrics, Harvard Medical School; Independent Investigator, Pediatric Oncology, Dana-Farber Cancer Institute; Co-Director, Pediatric Hematologic Malignancy, Boston Children’s Hospital & DFCI; Associate Member, Broad Institute of Harvard and MIT
Bromodomain Inhibition as a Novel Therapeutic Treatment for Pulmonary Fibrosis
David C. Budd, Ph.D., Honorary Lecturer, Department of Inflammation, Center for Rheumatology & Connective Tissue Diseases, University College London Medical School
BET Proteins as Critical Links between Chronic Inflammation, Insulin-Resistant Obesity and Certain Cancers
Gerald V. Denis, Ph.D., Associate Professor, Cancer Research Center, Department of Pharmacology & Medicine, Boston University School of Medicine
Mechanisms of BET Bromodomain Inhibition in the Control of Gene Expression
Robert J. Sims III, Ph.D., Senior Director of Biology, Constellation Pharmaceuticals, Inc.
Identification of Potent, BET Bromodomain Inhibitors for Treatment of Cancers
Hosahalli Subramanya, Ph.D., Senior Vice President, Structural Biology & Lead Generation, Aurigene Discovery Technologies, Ltd.
Targeting Bromodomains in NUT Midline Carcinoma
Christopher A. French, M.D., Assistant Professor, Department of Pathology, Harvard Medical School; Assistant Professor, Pathology, Brigham And Women's Hospital
CHD5 and H3: A Must-Read for Tumor Suppression
Alea A. Mills, Ph.D., Professor & Team Leader, Cold Spring Harbor Laboratory
Talk Title to be Announced
John Trzupek, Ph.D., MBA, Principal Scientist, Biotherapeutics, External Chemistry Innovation, Pfizer
From Epigenetic Mechanism to Targeted Therapy
Ming-Ming Zhou, Ph.D., Harold and Golden Lamport Professor and Chairman, Department of Structural & Chemical Biology; Co-Director, Experimental Therapeutics Institute, Icahn School of Medicine at Mount Sinai
Promoting Illiteracy: Inhibition of Methyl-Lysine Readers by Small Molecule Chemical Probes
Lindsey Ingerman James, Ph.D., Research Assistant Professor, Center for Integrative Chemical Biology & Drug Discovery Division of Chemical Biology and Medicinal Chemistry Eshelman School of Pharmacy; Visiting Scientist, Chemical Biology, GlaxoSmithKline, Research Triangle Park
Disrupting the Reader
John M. Denu, Ph.D., Director, Epigenetics Theme, Wisconsin Institute for Discovery; Professor, Biomolecular Chemistry, School of Medicine and Public Health, University of Wisconsin
Histone Binding Mechanisms and Specificities of PHD Fingers
Tatiana Kutateladze, Ph.D., Associate Professor, Department of Pharmacology, Anschutz Medical Campus, University of Colorado